The increase in serum levels of VEGF-A (MOC-3) [145] and the appearance of mutations in genes encoding proteins of the VEGF signaling pathway (MOC-5) [146] during bevacizumab treatment found in patients with colon cancer are potential predictive markers of a poor response to the drug in this type of cancer. This evidence concerns the gene VEGFA and colonic neoplasm.